Mkts

GT Biopharma, Inc.

NASDAQ: GTBP
$3.97+0.01 (+0.25%)
As of Nov 11, 2:18 PM ET

Key statistics

Day range
3.864.05
52-week range
4.2128.75
Today
Open4.04
Previous close3.97
Volume63.9K
Valuation
Market cap8.16M
P/E ratio—
EPS (TTM)-47.51
Income & risk
Dividend / yield—
Beta0.89
Avg volume57.7K
Discussion

GTBP News

Stories mentioning GTBP from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development413.001,376634.00363.001,0991,9301,3071,784
Sales General & Admin2,4354,2192,7481,150833.001,8332,2972,122
Total Operating Expenses1,987488.00
Operating Income (Loss)(2,848)(5,595)(3,382)(1,513)(1,932)(3,763)(3,604)(3,906)
Interest Income
Interest Expense
Other Expense156.00(27.00)
Pretax Income
Tax Provision
Net Income (Loss)(2,833)(5,708)8,299(30,169)(776.00)(3,775)(3,411)(3,710)
Earnings Per Share (Basic)(0.11)(1.04)1.04(10.92)(0.33)(1.99)(1.53)(2.17)
Earnings Per Share (Diluted)(0.11)(1.04)1.04(10.92)(0.33)(1.99)(1.53)(2.17)
Weighted Average Shares Outstanding (Basic)30,2835,5133,9412,7722,3451,8972,2341,712
Weighted Average Shares Outstanding (Diluted)30,2835,5133,9412,7722,3451,8972,2341,712

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About GTBP

GT Biopharma, Inc. (NASDAQ: GTBP) is a stock listed on the Nasdaq Stock Market under the ticker symbol GTBP. It last traded at $3.97 (Nov 11, 2026, 2:18 PM ET), up 0.3% on the day. That gives GT Biopharma a market capitalisation of $8.2M.

Over the past 52 weeks GTBP has traded between $4.21 and $28.75.

For the quarter ended Mar 31, 2026 it reported a net loss of $2.8M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$2.8M
Dec 31, 2025—-$5.7M
Sep 30, 2025—$8.3M
Jun 30, 2025—-$30.2M

From GT Biopharma’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…